ScreenIT
The Automated Screening Working Groups is a group of software engineers and biologists passionate about improving scientific manuscripts on a large scale. Our members have created tools that check for common problems in scientific manuscripts, including information needed to improve transparency and reproducibility. We have combined our tools into a single pipeline, called ScreenIT. We're currently using our tools to screen COVID preprints.
Latest preprint reviews
-
Rapid Support for Older Adults during the Initial Stages of the COVID-19 Pandemic: Results from a Geriatric Psychiatry Helpline
This article has 8 authors:Reviewed by ScreenIT
-
The Impact of the COVID-19 Pandemic on Mental Health, Occupational Functioning, and Professional Retention Among Health Care Workers and First Responders
This article has 9 authors:Reviewed by ScreenIT
-
Rapid increase of SARS-CoV-2 seroprevalence during the 2020 pandemic year in the population of the city of Tirana, Albania
This article has 4 authors:Reviewed by ScreenIT
-
MAIT cell activation and dynamics associated with COVID-19 disease severity
This article has 89 authors:Reviewed by ScreenIT
-
Novel Indicator to Ascertain the Status and Trend of COVID-19 Spread: Modeling Study
This article has 2 authors:Reviewed by ScreenIT
-
The Coronavirus 2019 pandemic in Canada: the impact of public health interventions on the course of the outbreak in Alberta and other provinces
This article has 8 authors:Reviewed by ScreenIT
-
Long-term monitoring of SARS-CoV-2 RNA in wastewater of the Frankfurt metropolitan area in Southern Germany
This article has 3 authors:Reviewed by ScreenIT
-
Coronavirus Disease 2019 Patients in Earlier Stages Exhaled Millions of Severe Acute Respiratory Syndrome Coronavirus 2 Per Hour
This article has 14 authors:Reviewed by ScreenIT
-
Non-communicable diseases, sociodemographic vulnerability and the risk of mortality in hospitalised children and adolescents with COVID-19 in Brazil: a cross-sectional observational study
This article has 7 authors:Reviewed by ScreenIT
-
Ivermectin as a potential COVID-19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens
This article has 2 authors:Reviewed by ScreenIT